Monalizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.

Monalizumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Monalizumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	8014	62
Beijing Solarbio Science & Tecnology Co., Ltd.	010-50973130 4009686088	3193328036@qq.com	China	29786	68
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1565	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10351	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24649	58
Biolab Reagents	027-65279366 18162686757	products@biolabreagent.com	China	9818	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 13720134139	orders@jknbiochem.com	China	5788	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11974	58
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd	021-59167510 18117107507	vip@med-life.cn	China	4997	58
Shanghai Youna Biopharmaceutical Co., Ltd	18164002430	511710754@qq.com	China	228	58

---

• Monalizumab
• Research Grade Monalizumab(DHD71901)
• 1228763-95-8